ClinicalTrials.gg
CompletedNCT04004208FIREFLEYEUpdated May 6, 2022Results posted

Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy

A Phase 3 interventional study of Eylea (Aflibercept, BAY86-5321) and Laser photocoagulation in Retinopathy of Prematurity (ROP), sponsored by Bayer. Completed at 90 sites in 27 countries. Open to participants aged Up to 32 Weeks. Per ClinicalTrials.gov, last updated 2022-05-06.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
Up to 32 Weeks
Sex
All
01

Study summary

The purpose of this study is to demonstrate how well aflibercept works in babies with ROP, comparing it with laser therapy. The study also has the objective to demonstrate how safe aflibercept is when used in babies, and describe how the drug moves into, through and out of the body.

02

Conditions studied

  • Retinopathy of Prematurity (ROP)
03

In context

Retinopathy of Prematurity

169 studies on the registry are indexed under Retinopathy of Prematurity; 27 are open to participants now.

This study's enrollment of 113 is above the median of 82 across 102 interventional studies indexed under Retinopathy of Prematurity.

Browse Retinopathy of Prematurity studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 32 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gestational age at birth ≤ 32 weeks or birth weight ≤ 1500 g
  • Subjects with treatment-naïve ROP classified according to the International Classification for ROP in at least one eye as:

    • Zone I Stage 1 plus, or 2 plus, or 3 non-plus or 3 plus, or
    • Zone II Stage 2 plus or 3 plus, or
    • Aggressive posterior retinopathy of prematurity (AP-ROP)
  • Weight at baseline (day of treatment) ≥ 800 g
  • Signed from parent(s)/legally authorized representative(s), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected chromosomal abnormality, genetic disorder or syndrome
  • Previous exposure to any IVT or systemic anti-vascular endothelial growth factor (VEGF) agent, including maternal exposure during pregnancy and/or during breastfeeding
  • neurological disease (eg, intraventricular hemorrhage grade 3 or higher, periventricular leukomalacia, congenital brain lesions significantly impairing optic nerve function, severe hydrocephalus with significantly increased intracranial pressure)
  • Pediatric conditions rendering the infant ineligible for study intervention at baseline or for repeated blood draws as evaluated by a NICU specialist and a study ophthalmologist
  • Presence of active ocular infection within 5 days of the first treatment
  • Advanced stages of ROP with partial or complete retinal detachment (ROP Stages 4 and 5)
  • ROP involving only Zone III
  • Ocular abnormalities that may interfere with the administration of study intervention or assessment of the study primary endpoint
  • Postnatal treatment with oral or intravenous at an equivalent dose of prednisone ≥ 1 mg/kg/day for > 2 weeks within 14 days of the first study intervention
  • Previous surgical or nonsurgical treatment for ROP (IVT anti-VEGF injection, ablative laser therapy, cryotherapy, and vitrectomy)
  • Participation of the subject or the mother in other clinical trials requiring administration of treatments (other than vitamins and minerals) at the time of screening, or within 30 days or 5 half-lives of administration of the previous study drug, whichever is longer
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    Aflibercept arm

    Subjects randomized to aflibercept will receive a intravitreal (IVT) injection of Dose A aflibercept per eligible eye at baseline and, if needed, up to a defined number of additional injections in each eye.

    Drug: Eylea (Aflibercept, BAY86-5321)

  • Active comparator
    Laser photocoagulation arm

    Subjects randomized to laser photocoagulation will receive treatment in each eligible eye at baseline. Retreatments may be administered if needed.

    Procedure: Laser photocoagulation

Interventions

  • Solution in a sterile glass vial, Dose A, IVT injection.

  • ProcedureLaser photocoagulation

    Transpupillary conventional laser ablative therapy

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With Absence of Active ROP and Unfavorable Structural Outcomes

    Active ROP was defined as ROP requiring treatment. Unfavorable structural outcomes included retinal detachment, macular dragging, macular fold, or retrolental opacity.

    Time frame: At 24 weeks after starting study treatment

Secondary outcomes

  1. Proportion of Participants Requiring Intervention With a Second Treatment Modality

    A second treatment modality for ROP was either rescue treatment or any other surgical or nonsurgical treatment for ROP (e.g. IVT anti-VEGF injection, ablative laser therapy, cryotherapy, or vitrectomy) captured as concomitant medication or surgery after study start.

    Time frame: From baseline (treatment) up to week 24.

  2. Proportion of Participants With Recurrence of ROP

    Participants with recurrence of ROP were defined as subjects requiring re-treatment or rescue treatment after in the past the absence of treatment-requiring active ROP had been confirmed by the investigator.

    Time frame: From baseline (treatment) up to week 24.

  3. Exploration of ROP Activity Scale Proposed by the International Neonatal Consortium

    Eyes were evaluated for change in ROP activity scale proposed by the International Neonatal Consortium (2018). ROP Activity Scale value range is from 0 to 22. Value 0 to 7 are considered mild, 8 to 12 are moderate, and 13 to 22 are severe. Value 0 means the best and value 22 means the worst. Eyes evaluation was done at baseline and each visit.

    Time frame: From baseline (treatment) up to week 24.

  4. Percentage of Participants With Ocular Treatment-emergent Adverse Events (TEAEs)

    A treatment-emergent adverse event (TEAE) was defined as an adverse event (AE) that was observed or reported after the first and not later than 30 days after the last administration of study treatment. Participants treated after week 21 were followed-up for adverse events up to week 28. Ocular TEAEs in treated eyes only were reported

    Time frame: From baseline (treatment) up to week 24

  5. Percentage of Participants With Ocular Serious Adverse Events (SAEs)

    Participants treated after week 21 were followed-up for adverse events up to week 28. Ocular SAEs in treated eyes only were reported.

    Time frame: From baseline (treatment) up to week 24

  6. Percentage of Participants With Systemic TEAEs

    A treatment-emergent adverse event (TEAE) was defined as an adverse event (AE) that was observed or reported after the first and not later than 30 days after the last administration of study treatment. Participants treated after week 21 were followed-up for adverse events up to week 28. Systemic TEAEs only were reported.

    Time frame: From baseline (treatment) up to week 24

  7. Percentage of Participants With Systemic SAEs

    Participants treated after week 21 were followed-up for adverse events up to week 28. Systemic SAEs only were reported.

    Time frame: From baseline (treatment) up to week 24

  8. Concentrations of Free Aflibercept in Plasma

    Blood samples for determination of aflibercept concentrations in plasma were collected in the aflibercept 0.4 mg arm at Day 1 (within 24 hours after injection), and at weeks 2 and 4, and if feasible also at weeks 8, 12 and 24. Statistics for week 8, 12, 24 not calculated as \> 1/3 of the concentrations were below the lower limit of quantification. Free Aflibercept Concentrations in Plasma were only measured in the Aflibercept 0.4 mg treatment arm.

    Time frame: From Day 1 up to week 24.

  9. Number of Participants With Anti-drug Antibodies (ADA)

    Immunogenicity was characterized by anti-drug antibody (ADA) responses in patients in the aflibercept 0.4 mg arm. Serum samples were taken at baseline prior to the injection and at 12 weeks after injection. ADA titers were summarized for 3 categories: Low (titer \<1,000); Moderate (1,000 ≤ titer ≤ 10,000); High (titer \>10,000). ADA in serum were only measured in the Aflibercept 0.4 mg treatment arm.

    Time frame: Baseline (treatment) and 12 weeks after aflibercept injection

  10. Number of Participants With Potential Neutralizing Antibodies (NAb)

    NAb status was evaluated for the samples that were positive in the ADA assay and had sufficient volume to analyze. NAb were only measured in participants with positive ADA in the Aflibercept 0.4 mg treatment arm

    Time frame: At 12 weeks after aflibercept injection

  11. Number of Aflibercept Administrations

    Total number of injections in both eyes.

    Time frame: From baseline (treatment) up to week 24.

  12. Number of Laser Treatments

    Total number of laser treatment in both eyes. If multiple sessions of laser treatment were necessary within 1 week from baseline, they were counted as a single treatment.

    Time frame: From baseline (treatment) up to week 24.

07

Results

Posted May 6, 2022

Participant flow

Study was conducted at 64 centers in 27 countries or regions, between 25-SEP-2019 (first participant first visit) and 12-Feb-2021 (last participant last visit).

Participant flow — Overall Study
MilestoneAflibercept 0.4 mgLaser Photocoagulation
Started7538
Saf7538
Pks750
Aas750
Completed6836
Not completed72
Withdrew: Withdrawal by parent/guardian11
Withdrew: Death30
Withdrew: Covid-19 pandemic10
Withdrew: Physician decision10
Withdrew: Adverse event11

Outcome measures

PrimaryProportion of Participants With Absence of Active ROP and Unfavorable Structural Outcomes

Active ROP was defined as ROP requiring treatment. Unfavorable structural outcomes included retinal detachment, macular dragging, macular fold, or retrolental opacity.

Time frame:
At 24 weeks after starting study treatment
Reported as:
Number · Proportion of participants
Proportion of Participants With Absence of Active ROP and Unfavorable Structural Outcomes
Proportion of participantsAflibercept 0.4 mgLaser Photocoagulation
Proportion of Participants With Absence of Active ROP and Unfavorable Structural Outcomes0.8550.821
Statistical analysis
  • Aflibercept 0.4 mg vs Laser Photocoagulation · Difference in proportions: 0.034 · 90% CI -0.08 to 0.162
SecondaryProportion of Participants Requiring Intervention With a Second Treatment Modality

A second treatment modality for ROP was either rescue treatment or any other surgical or nonsurgical treatment for ROP (e.g. IVT anti-VEGF injection, ablative laser therapy, cryotherapy, or vitrectomy) captured as concomitant medication or surgery after study start.

Time frame:
From baseline (treatment) up to week 24.
Reported as:
Number · Proportion of participants
Proportion of Participants Requiring Intervention With a Second Treatment Modality
Proportion of participantsAflibercept 0.4 mgLaser Photocoagulation
Proportion of Participants Requiring Intervention With a Second Treatment Modality0.0720.096
Statistical analysis
  • Aflibercept 0.4 mg vs Laser Photocoagulation · Difference in proportions: -0.023 · 90% CI -0.11 to 0.046
SecondaryProportion of Participants With Recurrence of ROP

Participants with recurrence of ROP were defined as subjects requiring re-treatment or rescue treatment after in the past the absence of treatment-requiring active ROP had been confirmed by the investigator.

Time frame:
From baseline (treatment) up to week 24.
Reported as:
Number · Proportion of participants
Proportion of Participants With Recurrence of ROP
Proportion of participantsAflibercept 0.4 mgLaser Photocoagulation
Proportion of Participants With Recurrence of ROP0.1610.063
Statistical analysis
  • Aflibercept 0.4 mg vs Laser Photocoagulation · Difference in proportions: 0.096 · 90% CI 0.019 to 0.175
SecondaryExploration of ROP Activity Scale Proposed by the International Neonatal Consortium

Eyes were evaluated for change in ROP activity scale proposed by the International Neonatal Consortium (2018). ROP Activity Scale value range is from 0 to 22. Value 0 to 7 are considered mild, 8 to 12 are moderate, and 13 to 22 are severe. Value 0 means the best and value 22 means the worst. Eyes evaluation was done at baseline and each visit.

Time frame:
From baseline (treatment) up to week 24.
Reported as:
Mean · Scores on a scale
Exploration of ROP Activity Scale Proposed by the International Neonatal Consortium
Scores on a scaleAflibercept 0.4 mgLaser Photocoagulation
Baseline16.20 ± 2.8115.63 ± 3.53
Change from baseline to Week 24-15.42 ± 4.46-14.77 ± 4.19
SecondaryPercentage of Participants With Ocular Treatment-emergent Adverse Events (TEAEs)

A treatment-emergent adverse event (TEAE) was defined as an adverse event (AE) that was observed or reported after the first and not later than 30 days after the last administration of study treatment. Participants treated after week 21 were followed-up for adverse events up to week 28. Ocular TEAEs in treated eyes only were reported

Time frame:
From baseline (treatment) up to week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Ocular Treatment-emergent Adverse Events (TEAEs)
Percentage of participantsAflibercept 0.4 mgLaser Photocoagulation
Percentage of Participants With Ocular Treatment-emergent Adverse Events (TEAEs)38.736.8
SecondaryPercentage of Participants With Ocular Serious Adverse Events (SAEs)

Participants treated after week 21 were followed-up for adverse events up to week 28. Ocular SAEs in treated eyes only were reported.

Time frame:
From baseline (treatment) up to week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Ocular Serious Adverse Events (SAEs)
Percentage of participantsAflibercept 0.4 mgLaser Photocoagulation
Percentage of Participants With Ocular Serious Adverse Events (SAEs)13.37.9
SecondaryPercentage of Participants With Systemic TEAEs

A treatment-emergent adverse event (TEAE) was defined as an adverse event (AE) that was observed or reported after the first and not later than 30 days after the last administration of study treatment. Participants treated after week 21 were followed-up for adverse events up to week 28. Systemic TEAEs only were reported.

Time frame:
From baseline (treatment) up to week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic TEAEs
Percentage of participantsAflibercept 0.4 mgLaser Photocoagulation
Percentage of Participants With Systemic TEAEs52.063.2
SecondaryPercentage of Participants With Systemic SAEs

Participants treated after week 21 were followed-up for adverse events up to week 28. Systemic SAEs only were reported.

Time frame:
From baseline (treatment) up to week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic SAEs
Percentage of participantsAflibercept 0.4 mgLaser Photocoagulation
Percentage of Participants With Systemic SAEs24.036.8
SecondaryConcentrations of Free Aflibercept in Plasma

Blood samples for determination of aflibercept concentrations in plasma were collected in the aflibercept 0.4 mg arm at Day 1 (within 24 hours after injection), and at weeks 2 and 4, and if feasible also at weeks 8, 12 and 24. Statistics for week 8, 12, 24 not calculated as \> 1/3 of the concentrations were below the lower limit of quantification. Free Aflibercept Concentrations in Plasma were only measured in the Aflibercept 0.4 mg treatment arm.

Time frame:
From Day 1 up to week 24.
Reported as:
Mean · ng/mL
Concentrations of Free Aflibercept in Plasma
ng/mLAflibercept 0.4 mg
WEEK 0, DAY 1480.607 ± 884.724
WEEK 2218.965 ± 358.933
WEEK 4133.093 ± 205.052
SecondaryNumber of Participants With Anti-drug Antibodies (ADA)

Immunogenicity was characterized by anti-drug antibody (ADA) responses in patients in the aflibercept 0.4 mg arm. Serum samples were taken at baseline prior to the injection and at 12 weeks after injection. ADA titers were summarized for 3 categories: Low (titer \<1,000); Moderate (1,000 ≤ titer ≤ 10,000); High (titer \>10,000). ADA in serum were only measured in the Aflibercept 0.4 mg treatment arm.

Time frame:
Baseline (treatment) and 12 weeks after aflibercept injection
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADA)
ParticipantsAflibercept 0.4 mg
Baseline — ADA positive response0
Baseline — ADA negative response75
Week 12 — ADA positive response1
Week 12 — ADA negative response74
SecondaryNumber of Participants With Potential Neutralizing Antibodies (NAb)

NAb status was evaluated for the samples that were positive in the ADA assay and had sufficient volume to analyze. NAb were only measured in participants with positive ADA in the Aflibercept 0.4 mg treatment arm

Time frame:
At 12 weeks after aflibercept injection
Reported as:
Count of participants · Participants
Number of Participants With Potential Neutralizing Antibodies (NAb)
ParticipantsAflibercept 0.4 mg
Number of Participants With Potential Neutralizing Antibodies (NAb)0
SecondaryNumber of Aflibercept Administrations

Total number of injections in both eyes.

Time frame:
From baseline (treatment) up to week 24.
Reported as:
Count of participants · Participants
Number of Aflibercept Administrations
ParticipantsAflibercept 0.4 mgLaser Photocoagulation
0 aflibercept administration034
1 aflibercept administration40
2 aflibercept administrations553
3 aflibercept administrations61
4 aflibercept administrations100
SecondaryNumber of Laser Treatments

Total number of laser treatment in both eyes. If multiple sessions of laser treatment were necessary within 1 week from baseline, they were counted as a single treatment.

Time frame:
From baseline (treatment) up to week 24.
Reported as:
Count of participants · Participants
Number of Laser Treatments
ParticipantsAflibercept 0.4 mgLaser Photocoagulation
0 laser treatment700
1 laser treatment34
2 laser treatments230
3 laser treatments01
4 laser treatments02
6 laser treatments01

Adverse events

Collected over After the first administration and not later than 30 days after the last administration of study treatment, up to 24 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept 0.4 mg3/75 (4%)9/75 (12%)53/75 (70.7%)
Laser Photocoagulation0/38 (0%)10/38 (26.3%)23/38 (60.5%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventAflibercept 0.4 mgLaser Photocoagulation
Retinal detachmentEye disorders3/752/38
Infantile apnoeaRespiratory, thoracic and mediastinal disorders0/752/38
Retinal haemorrhageEye disorders2/750/38
BronchiolitisInfections and infestations2/751/38
Pulmonary valve stenosisCardiac disorders0/751/38
Necrotising colitisGastrointestinal disorders0/751/38
ConjunctivitisInfections and infestations0/751/38
RhinitisInfections and infestations0/751/38
C-reactive protein increasedInvestigations0/751/38
ApnoeaRespiratory, thoracic and mediastinal disorders0/751/38
Most frequent other events
Showing 10 of 107
Most frequent other events
EventAflibercept 0.4 mgLaser Photocoagulation
Retinal haemorrhageEye disorders4/755/38
Eyelid oedemaEye disorders2/753/38
Umbilical herniaGastrointestinal disorders1/753/38
ConjunctivitisInfections and infestations3/753/38
Haemorrhage subcutaneousSkin and subcutaneous tissue disorders0/753/38
Conjunctival haemorrhageEye disorders4/750/38
AnaemiaBlood and lymphatic system disorders1/752/38
Anaemia neonatalBlood and lymphatic system disorders0/752/38
Bacterial disease carrierInfections and infestations0/752/38
ApnoeaRespiratory, thoracic and mediastinal disorders2/752/38

Baseline characteristics

SAF

Age, Continuous
Age, Continuous(weeks)Aflibercept 0.4 mgLaser PhotocoagulationTotal
Mean26.43 ± 2.126 ± 1.626.29 ± 1.9
Age, Customized
Age, Customized(Participants)Aflibercept 0.4 mgLaser PhotocoagulationTotal
In utero000
Preterm newborn infants (gestational age < 37 wks)7538113
Newborns (0-27 days)000
Infants and toddlers (28 days-23 months)000
Children (2-11 years)000
Adolescents (12-17 years)000
Adults (18-64 years)000
From 65-84 years000
85 years and over000
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept 0.4 mgLaser PhotocoagulationTotal
Female341953
Male411960
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Aflibercept 0.4 mgLaser PhotocoagulationTotal
White552883
Black or African American202
Asian Indian022
Chinese404
Japanese10616
Korean213
Asian: Other101
American Indian or Alaska Native011
Multiple101
ROP classification by investigator
ROP classification by investigator(Participants)Aflibercept 0.4 mgLaser PhotocoagulationTotal
Zone I excluding AP-ROP15722
Zone II excluding AP-ROP462672
AP-ROP: Zone I12416
AP-ROP: Zone II213
08

Study locations

90 sites
  • Many Locations
    Multiple Locations, Argentina
  • Hospital Público Descentralizado "Dr. Guillermo Rawson"
    San Juan, 5400, Argentina
  • Kepler Universitätsklinikum Campus III
    Linz, 4021, Austria
  • Many Locations
    Multiple Locations, Austria
  • AZ St-Jan Brugge Oostende AV
    Brugge, 8000, Belgium
  • Many Locations
    Multiple Locations, Belgium
  • Hospital das Clínicas de Botucatu - UNESP Botucatu
    Botucatu, Sao Paulo 18618 970, Brazil
  • Many Locations
    Multiple Locations, Brazil
  • Unifesp/Epm
    Sao Paulo, 04023-061, Brazil
  • Many Locations
    Multiple Locations, Bulgaria
  • UMHAT Sveti Georgi
    Plovdiv, 4002, Bulgaria
  • Acibadem City Clinic Multiprofile Hospital for Active Treatm
    Sofia, 1407, Bulgaria
  • II SOGHAT Sheinovo
    Sofia, 1504, Bulgaria
  • SHOGAT Prof Dimitar Stamatov
    Varna, 9000, Bulgaria
  • Many Locations
    Multiple Locations, Czechia
  • Fakultni nemocnice Ostrava
    Ostrava, 708 52, Czechia
  • Vseobecna fakultni nemocnice v Praze
    Praha 2, 12808, Czechia
  • P & A KYRIAKOU Children's Hospital
    Athens, 11527, Greece
  • University General Hospital of Ioannina
    Ioannina, 45500, Greece
  • Many Locations
    Multiple Locations, Greece
  • Papageorgiou General Hospital of Thessaloniki
    Thessaloniki, 56403, Greece
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • Many Locations
    Multiple Locations, Hong Kong
  • EKBC, Uj Szent Janos Korhaz es Szakrendelo
    Budapest, 1125, Hungary
  • Many Locations
    Multiple Locations, Hungary
  • Many Locations
    Multiple Locations, Israel
  • Kaplan Medical Center
    Rehovot, 7661041, Israel
  • IRCCS Ospedale Pediatrico Bambino Gesù
    Roma, Lazio 00165, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Roma, Lazio 00168, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milano, Lombardia 20122, Italy
  • A.O. di Perugia
    Perugia, Umbria 06129, Italy
  • Many Locations
    Multiple Locations, Italy
  • University of Occupational and Environmental Health
    Kitakyushu, Fukuoka 807-8556, Japan
  • Kurume University Hospital
    Kurume, Fukuoka 830-0011, Japan
  • Okinawa Prefectural Nanbu Medical Center and Children's MC
    Shimajiri-gun, Okinawa 901-1193, Japan
  • Tokyo Metropolitan Children's Medical Center
    Fuchu, Tokyo 183-8561, Japan
  • Showa University Hospital
    Shinagawa, Tokyo 142-8666, Japan
  • Tokyo Metropolitan Bokutoh Hospital
    Sumida-ku, Tokyo 130-8575, Japan
  • Tokyo Metropolitan Ohtsuka Hospital
    Toshima-ku, Tokyo 170-8476, Japan
  • Kyushu University Hospital
    Fukuoka, 812-8582, Japan
  • Fukuoka University Hospital
    Fukuoka, 814-0180, Japan
  • Fukushima Medical University Hospital
    Fukushima, 960-1295, Japan
  • Many Locations
    Multiple Locations, Japan
  • Saitama Children's Medical Center
    Saitama, 330-8777, Japan
  • Soon Chun Hyang University Cheonan Hospital
    Cheonan-si, Chungcheongnamdo, Korea, Republic of
  • Many Locations
    Multiple Locations, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Hospital Kuala Lumpur
    Kuala Lumpur, 50586, Malaysia
  • Many Locations
    Multiple Locations, Malaysia
  • Many Locations
    Multiple Locations, Netherlands
  • Maxima Medisch Centrum, locatie Veldhoven
    Veldhoven, 5504 DB, Netherlands
  • Many Locations
    Multiple Locations, Poland
  • Ginekologiczno-Polozniczy SK UM im. K. Marcinkowskiego
    Poznan, 60-535, Poland
  • Hospital Prof. Dr. Fernando Fonseca
    Amadora, Lisboa 2720-276, Portugal
  • CHLO - Hospital Sao Francisco Xavier
    Lisboa, 1449-005, Portugal
  • Many Locations
    Multiple Locations, Portugal
  • Clinical Emergency County Hospital
    Cluj-Napoca, Cluj 400006, Romania
  • Spitalul Clinic de Obstretica si Ginecologie "Cuza Voda"
    Iasi, 700038, Romania
  • Many Locations
    Multiple Locations, Romania
  • FSAI NMRC IRTC "Eye Microsurgery", Kaluga's Branch
    Kaluga, 248007, Russian Federation
  • Russian National Scientific Medical University
    Moscow, 117997, Russian Federation
  • FGBUZ "NPC of special children care n.a. Voino-Yaseneckogo"
    Moscow, 119620, Russian Federation
  • Many Locations
    Multiple Locations, Russian Federation
  • Pediatric Medical University
    Saint-Petersburg, 194100, Russian Federation
  • City Children Hospital ¿1
    Saint-Petersburg, 198205, Russian Federation
  • Many Locations
    Multiple Locations, Singapore
  • KK Women's and Children's Hospital
    Singapore, 229899, Singapore
  • Narodny ustav detskych chorob
    Bratislava, 833 41, Slovakia
  • Many Locations
    Multiple Locations, Slovakia
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario "La Paz"
    Madrid, 28046, Spain
  • Many Locations
    Multiple Locations, Spain
  • Hospital Regional de Málaga
    Málaga, 29011, Spain
  • Sahlgrenska Universitetssjukhuset
    Göteborg, Sweden
  • Many Locations
    Multiple Locations, Sweden
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung, 80756, Taiwan
  • Many Locations
    Multiple Locations, Taiwan
  • Mackay Memorial Hospital
    Taipei, 10449, Taiwan
  • S.B.U. Adana Sehir Egitim ve Arastirma Hastanesi
    Adana, 4522, Turkey
  • Hacettepe Universitesi Tip Fakultesi
    Ankara, 06100, Turkey
  • Baskent Universitesi Tip Fakultesi Hastanesi
    Ankara, 06490, Turkey
  • Gazi Universitesi Tip Fakultesi
    Ankara, 06500, Turkey
  • Saglik Bilimleri Universitesi Antalya EA Hastanesi
    Antalya, 07100, Turkey
  • Eskisehir Osmangazi Universitesi Tip Fakultesi
    Eskisehir, 26480, Turkey
  • Many Locations
    Multiple Locations, Turkey
  • Many Locations
    Multiple Locations, Ukraine
  • MI"Odesa Regional Children's Clinical Hospital"
    Odesa, 65031, Ukraine
  • Birmingham Womens Hospital
    Birmingham, B15 2TG, United Kingdom
  • Many Locations
    Multiple Locations, United Kingdom
09

References and documents

Publications

  • Stahl A, Sukgen EA, Wu WC, Lepore D, Nakanishi H, Mazela J, Moshfeghi DM, Vitti R, Athanikar A, Chu K, Iveli P, Zhao F, Schmelter T, Leal S, Kofuncu E, Azuma N; FIREFLEYE Study Group. Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial. JAMA. 2022 Jul 26;328(4):348-359. doi: 10.1001/jama.2022.10564. PubMed 35881122 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Feb 2021, 16 months.

Results were first posted in May 2022, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2019
First posted
Jul 1, 2019
StartActual
Sep 25, 2019
Primary completionActual
Feb 12, 2021
CompletionActual
Feb 12, 2021
Results first posted
May 6, 2022
Last update
May 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04004208
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jul 1, 2019
Start date
Sep 25, 2019
Primary completion
Feb 12, 2021
Completion
Feb 12, 2021
Results posted
May 6, 2022
Last update
May 6, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion